Global Blood Therapeutics, Inc.
http://www.globalbloodtx.com/index.php
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Global Blood Therapeutics, Inc.
Cardio Catch-Up: Medtronic, Abbott, Ancora Devices Headline ACC, CRT, THT
Medtech Insight’s Cardiovascular Catch-Up highlights recent news on cardiovascular tech innovations that you may have missed. This edition focuses on clinical trial presentations from three recent conferences: American College of Cardiology in New Orleans, Cardiovascular Research Technologies in Washington, DC, and Technology and Heart Failure Therapeutics in Boston.
Pfizer Pays $43bn For Seagen With Goal Of Rapidly, Globally Advancing ADCs
Pfizer expects its acquisition of Seagen to result in $10bn in new revenue by 2030 as the big pharma applies its resources to the target company’s pioneering antibody-drug conjugate technology.
Deals In 2023: Partnerships And Modest M&A
Mid-sized M&A, collaborations, creative financing, and biotech consolidation will feature in 2023. IPOs and follow-ons play bit-parts.
Pfizer In Pole Position To Benefit From Novartis Sickle Cell Drug Setback
Pfizer joined Novartis as the market leader in sickle cell disease when it acquired Global Blood Therapeutics last year. The US giant's Oxbryta may now move ahead following a clinical and regulatory setback for the Swiss major's Adakveo.
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice